Novel antileukemic compound with sub-micromolar potency against STAT5 addicted myeloid leukemia cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Signal Transducer and Activator of Transcription 5A and 5B (STAT5A/5B) are crucial in myeloid leukemias.
• Inhibiting STAT5A/5B blocks leukemia cell growth and survival, and overcomes chemotherapy resistance.

Purpose of the Study:

• To develop novel derivatives of the lead compound 17f with enhanced antileukemic activity.
• To identify new compounds targeting STAT5A/5B signaling in myeloid leukemias.

Main Methods:

• Pharmacological modification of a lead compound (17f).
• Screening assays to evaluate antileukemic activity and mechanism of action.
• Assessment of STAT5 phosphorylation and expression levels.

Main Results:

• Identified 14a, an aminopyrimidine derivative, as a potent antileukemic compound.
• 14a inhibits myeloid leukemia cell growth at sub-micromolar concentrations.
• 14a targets STAT5 phosphorylation and STAT5B expression, overcoming chemotherapy resistance.

Conclusions:

• Compound 14a demonstrates significant potential as a therapeutic agent for myeloid leukemias.
• 14a offers a dual mechanism of action by inhibiting STAT5 signaling and overcoming drug resistance.
• Further development of 14a could lead to improved treatments for Chronic and Acute Myeloid leukemia.